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Abstract: The inflammatory component of atherogenesis has been increasingly recognized
over the last decade. Inflammation participates in all stages of atherosclerosis, not only during
initiation and during evolution of lesions, but also with precipitation of acute thrombotic
complications. The metabolic syndrome is associated with increased risk for development of
both cardiovascular disease and type-2 diabetes in humans. Central obesity and insulin
resistance are thought to represent common underlying factors of the syndrome, which features
a chronic low-grade inflammatory state. Diagnosis of the metabolic syndrome occurs using
defined threshold values for waist circumference, blood pressure, fasting glucose and
dyslipidemia. The metabolic syndrome appears to affect a significant proportion of the
population. Therapeutic approaches that reduce the levels of proinflammatory biomarkers
and address traditional risk factors are particularly important in preventing cardiovascular
disease and, potentially, diabetes. The primary management of metabolic syndrome involves
healthy lifestyle promotion through moderate calorie restriction, moderate increase in physical
activity and change in dietary composition. Treatment of individual components aims to control
atherogenic dyslipidemia using fibrates and statins, elevated blood pressure, and
hyperglycemia. While no single treatment for the metabolic syndrome as a whole yet exists,
emerging therapies offer potential as future therapeutic approaches.
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Metabolic syndrome
It has been known for more than 40 years that the risk factors for coronary heart
disease (CHD) include hypertension, elevated levels of low-density lipoprotein
cholesterol (LDL-C), smoking, and type-2 diabetes. Yet, extensive research has
established that several of these cardiovascular risk factors cluster to a greater degree
than can be explained by chance. In the last few years, this clustering of symptoms
has been ascribed to a specific condition: the metabolic syndrome (MS). The MS is
a cluster of the most dangerous heart attack risk factors: diabetes or prediabetes,
abdominal obesity, changes in cholesterol and high blood pressure (Eckel et al 2005).
The basis for this aggregation of metabolic disorders has been investigated in an
epidemiological analysis carried out in the adult population of a small Pacific island,
leading to the identification of four independent factors that explained 73% of the
total variance (Shmulewitz et al 2001). This refinement in the clustering, however, is
lost when factors are all packaged together. In a re-analysis of the West of Scotland
Coronary Prevention Study (WOSCOPS), risk prediction increased with the number
of metabolic abnormalities (Sattar et al 2003). Evidence suggests that it is the exact
nature of the cluster which appears to bring additional risk over and above that which
would be expected from each of the components (Reilly and Rader 2003). It has
been argued, though, that the combination of risk factors does not add up to a more
significant or higher cardiovascular risk than the individual components (Kahn et al
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2005). Whether or not it is accepted that MS is a specific
disease entity or just a constellation of factors, the prevalence
of this condition is increasing worldwide, and patients need
to improve these risk factors through either lifestyle or
pharmacological approaches to reduce the odds of
developing diabetes and cardiovascular disease.
MS appears to affect a significant proportion of the
population. While up to 80% of the almost 200 million adults
worldwide with diabetes will die of cardiovascular disease,
people with MS are also at increased risk, being twice as
likely to die from, and three times as likely to have a heart
attack or stroke compared with people without the syndrome
(Isomaa et al 2001). People with MS have a 5-fold greater
risk of developing type-2 diabetes if not already present
(Stern et al 2004). This puts MS and diabetes way ahead of
HIV/AIDS in morbidity and mortality terms, yet the problem
is not as well recognized.
Definitions and prevalence of MS
Two somewhat different definitions of the syndrome have
been proposed: the first one by the World Health
Organization (WHO) (Alberti and Zimmet 1998), and the
second by the US National Cholesterol Education Program
(NCEP) in 2001 (NCEP 2001). Both definitions share the
essential components: glucose intolerance, obesity,
hypertension, and dyslipidemia. They do differ, however,
in detail and criteria (Table 1). Building on the earlier
definitions, the new consensus definition proposed by the
International Diabetes Federation in April 2005 is mainly
based on abdominal obesity as a central core of the
syndrome. It avoids the need for measurements that may
only be available in research settings. For a person to be
defined as having MS, the new definition requires the
presence of central obesity, plus two of the following four
additional factors: raised triglycerides, reduced high-density
lipoprotein cholesterol (HDL-C), raised blood pressure, or
raised fasting plasma glucose level. Gender and, for the first
time, ethnicity-specific cut-points for central obesity as
measured by waist circumference are included (Table 1). It
should be pointed out that these are operational definitions
and a definition using cluster analysis with likelihood of
having high risk cluster as continuous variable may be more
useful.
Although the use of different definitions up until now
has made it difficult to estimate the prevalence of MS and
make comparisons between nations, recent data from
Australia and the US provides a broad estimate of 20%–
25% of the adult population (Dunstan et al 2002; Ford et al
2002). Of the 8608 participants in the Third US National
Health and Nutrition Examination Survey (NHANES III),
all aged at least 20 years, the age-adjusted prevalence of
MS was approximately 25%. The incidence rate increases
with age and the prevalence of CHD is increased in patients
with this condition. Most importantly, MS heavily affects
Table 1 Definitions of the metabolic syndrome
World Health Organization NCEP ATPIII International Diabetes Federation
At least one of the following criteria of insulin Abdominal obesity as defined by:  Central obesity defined as: 
resistance and impaired glucose regulation waist circumference >102 cm in men waist circumference ≥94 cm for Europid men
impaired FPG ≥110 mg/dL waist circumference >88 cm in women waist circumference ≥80 cm for Europid women
impaired PG tolerance (2h PG ≥140 mg/dL) TG ≥150 mg/dL with ethnicity specific values for other groups
elevated insulin levels (4th quartile of reference) HDL-C in men <40 mg/dL, Plus any two of the following four factors:
diabetes in women <50 mg/dL raised TG level: ≥150  mg/dL (1.7  mmol/L), or
Plus two or more of the following: BP ≥130/85 mm Hg specific treatment for this lipid abnormality
Systolic BP  ≥140 mm Hg and/or diastolic FPG ≥110 mg/dL reduced HDL-C: <40  mg/dL (1.03  mmol/L) in
BP ≥90 mm Hg males and <50 mg/dL (1.29 mmol/L) in females, or
TG ≥150 mg/dL and/or HDL-C <35 mg/dL for men specific treatment for this lipid abnormality
and <40 mg/dL for women raised BP: systolic BP ≥130 or diastolic BP
Central obesity: waist/hip ratio >0.90 for men and ≥85  mm Hg, or treatment of previously
0.85 for women and/or BMI >30 kg/m2 diagnosed hypertension
Microalbuminuria: urinary albumin excretion rate raised FPG ≥100  mg/dL (5.6  mmol/L),
≥20 mg/ml or albumin/creatinine ratio ≥30 mg/g or previously diagnosed type-2 diabetes
If above 5.6 mmol/L or 100 mg/dL, oral
glucose tolerance test is strongly recommended
but is not necessary to define presence of the
syndrome. 
Abbreviations: ATP,  Adult Treatment Panel; BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol;
NCEP, National Cholesterol Education Program; PG, plasma glucose; TG, triglycerides.Vascular Health and Risk Management 2006:2(2) 147
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the younger generations. Looking at more than 1900
children and teenagers aged 12 to 19 living in the US, over
60% of them have at least one metabolic abnormality using
a pediatric definition based on the NCEP criteria and almost
10% have MS (de Ferranti et al 2004). The racial and ethnic
distribution for MS in this study was similar to that seen in
adults, whereby Mexican-Americans have the greatest
prevalence (13%) followed by non-Hispanic whites (11%).
Thus, the clustering of metabolic abnormalities in children
raises major concerns and warrants risk-reducing
interventions in the form of a population approach. In a
rather similar study, the effect of different degrees of obesity
in children on the prevalence of MS and its relationship to
insulin resistance was examined in 439 obese, 31
overweight, and 20 nonobese children and adolescents. In
this cohort, the overall prevalence of MS is 38.7% in
moderately obese subjects and 49.7% in severely obese
subjects (Weiss et al 2004). C-reactive protein (CRP) and
interleukin 6 (IL-6), which are established biomarkers of
inflammation and potential predictors of adverse
cardiovascular outcomes, rise with the degree of obesity
whereas adiponectin, a biomarker of insulin sensitivity,
decrease as obesity increased. These data suggest that
pathophysiological mechanisms related to MS in adults are
already operative in childhood, which predisposes to
increased risk for development of both CHD and type-2
diabetes.
MS is associated with excess
mortality
According to the NCEP definition, roughly one third of
middle-aged men and women in most Western countries
have MS. This represents a potential public health issue, as
MS is associated with an increased risk of mortality from
CHD, cardiovascular disease, and from all causes. In a
prospective cohort study, 1209 Finnish men aged 40 to 60
at baseline (1984–1989), who were free of cardiovascular
disease, cancer or diabetes, were followed through 1998.
In this cohort, men with MS were 3 to 4 times more likely
to die of CHD than were those without the syndrome (Lakka
et al 2002). Using data from 11 large population- or
occupational-based prospective cohort studies comprising
6156 nondiabetic men and 5356 women, the prevalence of
MS was found to be slightly higher in men (15.7%) than in
women (14.2%). These individuals have a 1.4-fold increased
risk of all-cause mortality and a 2.3 to 2.8 increased risk of
cardiovascular death (Hu et al 2004). Accordingly, a recent
prospective study describing the prevalence of MS in acute
myocardial infarction (AMI) and assessing its impact on
hospital outcomes demonstrates that almost half of all AMI
patients also suffer from MS (Zeller et al 2005). In this study,
the prevalence of MS was examined in 633 patients
hospitalized with AMI within 24 hours of the onset of
symptoms. Participants were diagnosed with MS according
to the NCEP definition and MS was more prevalent in
women and older patients. Analysis of the predictive value
of each of the five metabolic-syndrome components for
severe heart failure showed that hyperglycemia is the major
determinant. Given the ever-increasing prevalence of MS
worldwide, this finding has important clinical implications
and suggests the importance of evaluating glycemic control
during the acute phase of MI.
Factors contributing to the
development of MS
While the underlying cause of MS is still the subject of
intense debate, both abnormal abdominal fat distribution
and insulin resistance have been identified as potential, inter-
related causes. The flux of non-esterified fatty acids to the
liver is tied into visceral fat accumulation as a contributing
factor. Accordingly, MS in older men and women is
associated with excess accumulation of visceral abdominal
or intramuscular fat, even in normal-weight individuals
(Goodpaster et al 2005). This study examined 3035 adults
aged 70 to 79, of whom 42% were African Americans.
Prevalence of MS was 39% in the entire cohort and highest
in obese men and women. Using computed tomography to
assess fat distribution, it was found that visceral adipose
tissue was nearly 50% higher in participants with MS.
Higher subcutaneous adipose tissue as well as higher
intermuscular adipose tissue was significantly associated
with MS in normal-weight and overweight, but not in obese
men, and not in women. Regional fat distribution clearly
discriminates those with MS, particularly among the non-
obese. This implies that older men and women can have
normal body weight and even have relatively lower total
body fat but still have MS, due to the amount of adipose
tissue located intra-abdominally or interspersed within the
musculature.
Like steroid hormone receptors, nuclear peroxisome
proliferator-activated receptors (PPAR) are ligand-activated,
metabolic transcription factors containing ligand binding
and DNA binding domains. PPAR activation by specific
ligands results in either induction of repression of targetVascular Health and Risk Management 2006:2(2) 148
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gene expression. PPARα, which is expressed in tissues with
high-energy demands, is involved in the β-oxidation of fatty
acids. PPARγ, which is expressed predominantly in adipose
tissue, participates in adipogenesis, glucose homeostasis,
and lipid metabolism. PPAR activation can improve
metabolic parameters like glucose and lipid levels, but also
directly alter relevant vascular responses through regulation
of target genes including those encoding adhesion
molecules, the ATP-binding cassette transporter 1 (ABCA1),
lipoprotein lipase, cytokines, and chemokines (Chinetti-
Gbaguidi et al 2005). There have been indications that
PPARα are involved in the pathogenesis of insulin
resistance. For instance, PPARα knock-out mice are
protected from diet-induced insulin resistance probably
because of inhibition of PPARα-dependent fatty acid
oxidation (Tordjman et al 2001). By contrast, genetic defects
in PPARγ can recapitulate all the salient features of MS in
humans (Savage et al 2003). Therefore, PPARs are likely to
be involved in the development of MS and, accordingly,
can serve as potential therapeutic targets for the prevention
and treatment of MS (Berger et al 2005).
Inflammation: the missing link?
The measurement of markers of inflammation has been
proposed as a method to improve global cardiovascular risk
prediction. Among them are markers of systemic
inflammation produced in the liver, such as CRP. When
determined with a high sensitivity test, CRP is an
independent predictor of future cardiovascular events and
adds prognostic information to lipid screening. A wealth of
prospective studies relates baseline CRP levels to the risk
of first cardiovascular events among individuals with no
prior history of cardiovascular disease (Ridker 2003)
Although CRP level was not considered a MS marker by
NCEP ATP III, it is also increased in patients affected by
this syndrome. Ridker et al (2003) noted a gradual increase
in median CRP levels in relation to the number of markers
of MS in an 8-year follow-up of 14 719 initially healthy
American women. In middle-aged Finnish men who
participated in a population-based cohort study, CRP
concentrations above 3 mg/L were associated to the
development of MS, but the relationship was no longer
significant after adjustment for lifestyle- and insulin
resistance-related factors (Laaksonen et al 2004). It has been
argued that statin therapy reduces coronary events by virtue
of decreased levels of CRP independent from the effects on
LDL-C (Nissen et al 2005; Ridker et al 2005). Statins display
a variety of pleiotropic properties, including their ability to
induce dose-dependent decreases in the levels of CRP and
other inflammatory biomarkers (Albert et al 2001).
Secondary prevention data also demonstrate that therapies
designed to reduce inflammation after acute coronary
ischemia may improve cardiovascular outcomes (Hansson
2005).
Increasing evidence suggests that chronic, subclinical
inflammation is part of MS. The first demonstration thereof
pointed out that various components of MS are related to
inflammatory markers (CRP, fibrinogen, white cell count)
and that dyslipidemia, abdominal obesity, low insulin
sensitivity and hypertension parallel increasing levels of
CRP (Festa et al 2000). Results are consistent across a variety
of ethnic groups that differ in insulin sensitivity. In addition,
it is known that glucose and macronutrient intake causes
oxidative stress and inflammatory changes while insulin
displays antiinflammatory effects. As a result, increased
concentrations of tumor necrosis factor-α (TNF-α) and IL-
6 might interfere with insulin action by suppressing insulin
signal transduction (Dandona et al. 2004).
Several features of MS, including visceral obesity, are
associated with a low-grade inflammatory state (Table 2).
Highly sensitive CRP (hsCRP) levels in plasma tend to be
elevated in subjects with insulin resistance and obesity;
elevated levels of hsCRP are predictors of both CHD and
diabetes. The adipose tissue is a source of several molecules,
such as leptin, plasminogen activator inhibitor 1 (PAI-1),
TNF-α, angiotensinogen and IL-6, that are collectively
called adipokines and directly contribute to oxidative
damage and vascular inflammation (Dandona et al 2005).
Leptin was described to have procoagulant and
Table 2 The inflammatory component of the metabolic
syndrome
Vascular dysfunction
Endothelial dysfunction
Microalbuminuria
Proinflammatory state
Elevated hsCRP and SAA
Elevated inflammatory cytokines (TNF-α, IL-6)
Decreased adiponectin levels
Prothrombotic state
Increased antifibrinolytic factors (PAI-1)
Increased fibrinogen
Insulin resistance
Visceral adiposity
Abbreviations: hsCRP, high sensitivity C-reactive protein; IL-6, interleukin 6;
PAI-1, plasminogen activator inhibitor 1; SAA, serum amyloid A; TNF-α, tumor
necrosis factor-α.Vascular Health and Risk Management 2006:2(2) 149
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antifibrinolytic properties. Furthermore, leptin supports
thrombus formation and atherogenesis by amplifying
vascular inflammation and proliferation (Nieuwdorp et al
2005). TNF-α and leptin can also inhibit insulin-mediated
glucose uptake. Thus, increasing evidence implicates the
adipocyte as a pathophysiologic contributor to insulin
resistance and vascular disease. In contrast, adiponectin, also
derived from adipose tissue, circulates in low levels in obese
subjects and, importantly, inhibits inflammation and
promotes insulin sensitivity. Adiponectin decreases
endothelial expression of adhesion molecules (intercellular
adhesion molecule-1[CAM-1], vascular cell adhesion
molecule-1[VCAM-1], P-selectin), inhibits foam cell
formation in vitro and decreases macrophage phagocytic
activity (Yokota et al 2000). Yet resistin, which is expressed
primarily in macrophages and is correlated with markers of
inflammation (Reilly et al 2005), increases the expression
of VCAM-1 and ICAM-1 while enhancing that of monocyte
chemoattractant protein-1 (Verma et al 2003). Therefore,
adiponectin and resitin interfere with monocyte adherence
to vascular endothelium, further promoting monocytic
migration to the subendothelial space, one of the key events
in the development of atherosclerosis.
The relationship of adiponectin with markers of
inflammation, adiposity and insulin resistance was
investigated in obese individuals with and without MS.
Subjects with MS have significantly lower adiponectin and
higher TNF-α compared with subjects without MS. Despite
rapid weight loss through caloric restriction for 4–6 weeks,
adiponectin and TNF-α concentrations did not change
(Xydakis et al 2004). Patients with MS commonly have
additional less well-defined metabolic abnormalities
including hyperuricemia and raised CRP levels that may be
associated with increased cardiovascular risk. As chronic
subclinical inflammation appears to participate in the
progression of MS and other metabolic disorders, it has been
hypothesized that periodontal disease is one such subclinical
inflammation (Nishimura and Murayama 2001; Nishimura
et al 2005), because successful periodontal treatment may
improve metabolic control via reduction of circulating TNF-
α concentrations.
The newly proposed definition of MS from the
International Diabetes Federation does not include
inflammatory parameters. However, the proinflammatory
state is regarded as an additional metabolic criterium that
appears to be related to MS (Table 2). Elevated hsCRP and
serum amyloid protein A (not to be confused with Alzheimer
amyloid), elevated inflammatory cytokines (TNF-α, IL-6),
and decreased adiponectin plasma levels should be included
in research studies to help determine the predictive power
of these extra criteria for cardiovascular disease and/or
diabetes. The use of these additional factors in research is
intended to allow further modification of the definition and
its validation in different ethnic groups.
Treatment of MS
While no single treatment for the metabolic syndrome as a
whole exists yet, it is well established that lifestyle changes,
for example, changes in diet and an increase in exercise,
form the underlying strategy of treatment (Table 3). When
the lifestyle approach seems to be inadequate, it is necessary
to treat the individual components of MS so that a reduction
in the individual risk associated with each component will
likely contribute to reduce the overall impact on
cardiovascular disease and diabetes risk (Table 3).
The relevance of diet as a therapeutic strategy in MS is
emphasized in a recent study by Esposito and colleagues
(2004), who randomized 180 men and women with MS to
either a Mediterranean diet or a “prudent diet.” The nutrient
composition of the two diets (50%–60% carbohydrates, 15%
protein, <30% fat) was similar. After two years, while
physical activity levels had increased in both groups to the
same degree, patients on the Mediterranean diet lost more
weight than the control group and had lower plasma levels
of CRP and IL-6, as well as less insulin resistance. Likewise,
Table 3 Current therapeutic approaches to the treatment of
metabolic syndrome
Primary prevention
Healthy lifestyle promotion
Small weight loss
Moderate physical activity
Dietary restriction in calorie intake
Change in dietary composition
Drug intervention for treatment of individual components
Atherogenic dyslipidemia
Statins
Fibrates
Nicotinic acid
Elevated blood pressure
No particular agent is preferred, although ACE inhibitors and
angiotensin receptor blockers may carry advantage in patients with
metabolic disorders
Insulin resistance and hyperglycemia
Metformin
Thiazolidinediones
Acarbose
Orlistat
Abbreviations: ACE, angiotensin-converting enzyme.Vascular Health and Risk Management 2006:2(2) 150
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participants on the Mediterranean diet saw their total
cholesterol and triglycerides fall and their HDL-C rise over
the course of the study significantly more than did
participants on the prudent diet. In addition, endothelial
function improved in the Mediterranean diet group but
remained stable in the control group, although this difference
was not quite statistically significant, suggesting a potential
mechanistic explanation of benefit. Strikingly, after two
years on their respective diets, only 40 out of 90 patients in
the Mediterranean diet still had features of MS, compared
with 78 out of 90 in the control group. The results of this
study represent the first demonstration that a Mediterranean-
style diet rich in whole grains, fruits, vegetables, legumes,
walnuts, and olive oil might be effective in reducing both
the prevalence of MS and its associated cardiovascular risk.
The benefits of the diet might be through a reduction in
low-grade inflammation associated with MS. Conversely,
there are indications that marked reductions in fat intake
associated with exercise lead to increased levels of
circulating cytokines likely due to enhanced activity of the
immune system (Meksawan et al 2004).
In the Diabetes Prevention Program, more than 3200
men and women with impaired glucose tolerance were
examined and followed for 3 years (Orchard et al 2005).
These subjects were randomized to intensive lifestyle
changes (diet and exercise interventions), metformin therapy
(850 mg twice daily) or placebo. Incidence of MS at baseline
was over 50%. Among participants who did not have MS at
baseline, 53% of those in the placebo group went on to
develop MS over the mean 3.2 years of follow-up, compared
with 47% in the metformin group and 38% in the lifestyle-
intervention group. The risk reduction for MS development,
as evaluated by proportional hazard analysis, was 41% in
the lifestyle group and 17% in the metformin group
compared with placebo. Lifestyle interventions appeared
to have a positive impact on all of the parameters of MS but
HDL-C. By contrast, metformin was effective only at
reducing waist circumference and fasting glucose levels.
Lifestyle intervention not only prevented new cases of MS
but also led to an overall decline in the proportion of
participants with MS.
In a substudy from the Arterial biology for the
investigation of the treatment effects of reducing cholesterol
(ARBITER-2) trial (Taylor et al 2004) supporting the
addition of extended-release niacin to statin therapy to
increase HDL-C in patients with abnormal glucose
tolerance, changes in HDL-C were independently associated
with changes in carotid intima-media thickness in patients
with MS after controlling for individual MS determinants
(Taylor et al 2005). The utilization of nicotinic acid in
diabetic patients has, in the past, been considered
problematic due to its glucose-raising effects. Recent data,
however, indicate that despite the modest increase in serum
glucose levels the overall benefit of nicotinic acid treatment
is a marked reduction in cardiovascular events (Canner et
al 2005). A new post-hoc analysis of the Bezafibrate
Infarction Prevention (BIP) trial identified 1470 patients
with MS and revealed that in those patients treatment with
bezafibrate (400 mg/d) was associated with a reduced risk
of MI as compared with placebo, and cardiac mortality
showed borderline significance towards reduction
(Tenenbaum et al 2005). Even greater was the effect of
bezafibrate treatment on cardiac mortality reduction in those
patients with augmented features of MS, ie, with at least
four features of MS according to the ATPIII definition.
Similarly, a subgroup analysis from the Veterans Affairs
HDL Intervention Trial (VA-HIT) shows that the combined
events of MI, CHD death, and stroke were reduced more
with gemfibrozil at all levels of HDL-C or triglycerides with
insulin resistance than without insulin resistance.
Unexpectedly, the increases in HDL-C and decreases in
triglycerides with therapy were least in the presence of
insulin resistance for which the clinical benefit of drug was
greatest, suggesting that other properties of fibrate therapy
may be more beneficial than changes in lipid concentrations
(Robins et al 2003). Whereas statins remain the drug of
choice for patients who need to achieve the LDL-C goal,
fibrate therapy may represent an alternative for those with
a lipid profile typical of MS (Robins 2003). The concomitant
use of fibrates could be attractive in patients whose LDL-C
is controlled by statin therapy but whose HDL-C and/or
triglycerides are still inappropriate.
Ligands that activate PPARγ (thiazolidinediones) may
also prove useful because they have antiinflammatory
properties and exert direct effects on skeletal muscle that
promote insulin action and protect vascular endothelium
from the atherosclerotic process (Staels and Fruchart 2005).
The antiinflammatory properties of synthetic PPARγ
agonists may be explained, in part, by their ability to inhibit
production of TNF-α and other proinflammatory cytokines
as well as to increase adiponectin expression and secretion
(Cabrero et al 2002). Recent thiazolidinedione studies have
also demonstrated efficacy in delaying or preventing type-
2 diabetes in patients with impaired glucose tolerance (IGT)
and insulin resistance (Buchanan et al 2002; Durbin 2004).
It has not been ascertained yet whether any of the currentlyVascular Health and Risk Management 2006:2(2) 151
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available thiazolidinediones reduce the risk of
cardiovascular disease in subjects with MS, IGT, or diabetes.
New therapies are on the horizon that may address
several of the risk factors concurrently, which may have a
significant impact on reducing both cardiovascular and
diabetes morbidity and mortality. The multiple risk factor
approach has been tested in high-risk diabetic patients who
were assigned to an intensive multifactorial pharmacological
treatment including aspirin, angiotensin-converting enzyme
(ACE) inhibitors, dietary supplements, and other
medications to control known risk factors. This approach
reduced cardiovascular events as well as additional disease
conditions by about half with respect to standard therapy
(Gaede et al 2003). Clinical data should become available
soon for the new generation of PPAR agonists, which
interact with both PPARα and γ-receptors (the glitazars),
thereby combining lipid and glycaemic effects. In addition,
emerging therapies such as incretin mimetics (exenatide),
dipeptidyl peptidase IV inhibitors, protein tyrosine
phosphatase 1B inhibitors, leptin receptor antagonists, and
cannabinoid receptor blocking agents offer potential as
future therapies for MS.
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